Minerva Neurosciences

Historical price data

Minerva Neurosciences is a publicly traded, clinical-stage biotech company focused on addressing significant unmet medical needs in central nervous system disorders, particularly schizophrenia and Parkinson's disease. Founded in 2007, the company's core strategy centers on its specialized expertise in clinical trial design, aiming to demonstrate clear patient benefit through carefully selected endpoints and patient populations. While currently pre-revenue, its value proposition lies in its ability to potentially de-risk late-stage development in challenging CNS indications. The company faces the critical challenge of advancing its pipeline through clinical milestones with limited financial resources.

Clinical development expertise focused on designing innovative trials with patient-centric endpoints and strategic patient selection to de-risk development in central nervous system disorders.

Faces competition from large pharma and biotechs in both schizophrenia and Parkinson's disease psychosis. In negative symptoms, it races against other late-stage programs for first approval. In Parkinson's psychosis, it must compete against an established, approved therapy (pimavanserin) and other novel agents in development.